Dr Reddys gets EIR from USFDA for manufacturing plants at Duvvada
The company has received EIR from the United States Food and Drug Administration (USFDA) for the inspection conducted at the formulations manufacturing plants at Duvvada Visakhapatnam, Dr Reddy's Laboratories said in a regulatory filing.
New Delhi: Dr Reddy's Laboratories on Thursday said it has received establishment inspection report (EIR) from the US health regulator for its Visakhapatnam facility in Andhra Pradesh.
The company has received EIR from the United States Food and Drug Administration (USFDA) for the inspection conducted at the formulations manufacturing plants at Duvvada Visakhapatnam, Dr Reddy's Laboratories said in a regulatory filing.
Read Also: Dr Reddys unveils a generic version of Zyban ER tablets in the US
The inspection of the two facilities were completed by the USFDA on June 21 this year, it added.
"We have now received an EIR from the USFDA, indicating closure of this audit," the company said.
The USFDA gives EIR on closure of inspection of an establishment that is the subject of USFDA or USFDA-contracted inspection.
Read Also: Dr Reddys gets 8 USFDA observations for Duvvada facility in Andhra Pradesh
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd